Mirum Historical Balance Sheet

MIRM Stock

USD 44.27 0.46 1.03%

Trend analysis of Mirum Pharmaceuticals balance sheet accounts such as Total Current Liabilities of 91.4 M provides information on Mirum Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Mirum Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Mirum Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Mirum Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Mirum Pharmaceuticals is a good buy for the upcoming year.

Mirum Pharmaceuticals Inventory

23.43 Million

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.

About Mirum Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Mirum Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Mirum Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Mirum Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Mirum currently owns. An asset can also be divided into two categories, current and non-current.

Mirum Pharmaceuticals Balance Sheet Chart

At this time, Mirum Pharmaceuticals' Net Debt is very stable compared to the past year. As of the 26th of November 2024, Cash is likely to grow to about 300.6 M, while Accounts Payable is likely to drop about 5.9 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab Warrants Treasury Stock

Add Fundamental

Total Assets

Total assets refers to the total amount of Mirum Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Mirum Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Mirum Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Mirum Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Warrants

Securities that give the holder the right to purchase a company's stock at a specified price before a certain date. Warrants are similar to options but are typically issued directly by the company.

Most accounts from Mirum Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Mirum Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.At this time, Mirum Pharmaceuticals' Net Debt is very stable compared to the past year. As of the 26th of November 2024, Cash is likely to grow to about 300.6 M, while Accounts Payable is likely to drop about 5.9 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	32.0M	54.2M	77.4M	81.3M
Total Assets	294.7M	352.9M	646.6M	679.0M

Other Current Liab Total Assets

Mirum Pharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue
Total Assets		0.98	0.98	0.42	0.94	0.68	0.57	-0.99	0.8	0.84	0.87	-0.8	0.91	0.94	0.86	0.84	0.96	0.96	0.98	0.89	-0.8	0.86	-0.8	0.88	-0.95	-0.59
Other Current Liab	0.98		1.0	0.35	0.97	0.6	0.65	-0.99	0.83	0.76	0.85	-0.76	0.94	0.95	0.85	0.82	0.96	0.97	0.94	0.85	-0.76	0.79	-0.76	0.86	-0.96	-0.64
Total Current Liabilities	0.98	1.0		0.33	0.98	0.63	0.63	-1.0	0.86	0.74	0.86	-0.79	0.94	0.93	0.88	0.84	0.96	0.96	0.93	0.86	-0.79	0.79	-0.79	0.83	-0.98	-0.6
Total Stockholder Equity	0.42	0.35	0.33		0.29	-0.02	0.54	-0.31	0.07	0.59	0.01	-0.03	0.29	0.57	0.03	0.11	0.33	0.51	0.51	0.25	-0.03	0.27	-0.03	0.69	-0.27	0.02
Other Liab	0.94	0.97	0.98	0.29		0.62	0.65	-0.98	0.91	0.61	0.85	-0.78	0.94	0.9	0.89	0.89	0.97	0.93	0.85	0.83	-0.78	0.76	-0.78	0.73	-1.0	-0.47
Net Tangible Assets	0.68	0.6	0.63	-0.02	0.62		-0.18	-0.66	0.75	0.58	0.87	-0.96	0.56	0.39	0.81	0.85	0.61	0.45	0.66	0.78	-0.96	0.8	-0.96	0.37	-0.65	-0.18
Net Debt	0.57	0.65	0.63	0.54	0.65	-0.18		-0.6	0.38	0.34	0.22	-0.05	0.64	0.81	0.3	0.27	0.63	0.77	0.51	0.31	-0.05	0.22	-0.05	0.67	-0.62	-0.43
Retained Earnings	-0.99	-0.99	-1.0	-0.31	-0.98	-0.66	-0.6		-0.86	-0.75	-0.9	0.8	-0.96	-0.92	-0.9	-0.87	-0.98	-0.95	-0.93	-0.9	0.8	-0.84	0.8	-0.82	0.98	0.6
Accounts Payable	0.8	0.83	0.86	0.07	0.91	0.75	0.38	-0.86		0.41	0.86	-0.89	0.86	0.66	0.93	0.94	0.8	0.72	0.68	0.79	-0.89	0.71	-0.89	0.47	-0.92	-0.24
Cash	0.84	0.76	0.74	0.59	0.61	0.58	0.34	-0.75	0.41		0.65	-0.59	0.64	0.78	0.56	0.54	0.72	0.78	0.94	0.76	-0.59	0.79	-0.59	0.93	-0.62	-0.6
Cash And Short Term Investments	0.87	0.85	0.86	0.01	0.85	0.87	0.22	-0.9	0.86	0.65		-0.92	0.87	0.68	0.98	0.94	0.86	0.73	0.81	0.95	-0.92	0.93	-0.92	0.59	-0.88	-0.51
Common Stock Total Equity	-0.8	-0.76	-0.79	-0.03	-0.78	-0.96	-0.05	0.8	-0.89	-0.59	-0.92		-0.72	-0.54	-0.91	-0.92	-0.73	-0.61	-0.75	-0.84	1.0	-0.82	1.0	-0.48	0.8	0.28
Common Stock Shares Outstanding	0.91	0.94	0.94	0.29	0.94	0.56	0.64	-0.96	0.86	0.64	0.87	-0.72		0.88	0.91	0.85	0.92	0.91	0.84	0.9	-0.72	0.83	-0.72	0.75	-0.96	-0.55
Non Current Liabilities Total	0.94	0.95	0.93	0.57	0.9	0.39	0.81	-0.92	0.66	0.78	0.68	-0.54	0.88		0.69	0.67	0.93	1.0	0.91	0.75	-0.54	0.7	-0.54	0.94	-0.89	-0.61
Capital Surpluse	0.86	0.85	0.88	0.03	0.89	0.81	0.3	-0.9	0.93	0.56	0.98	-0.91	0.91	0.69		0.96	0.85	0.74	0.77	0.94	-0.91	0.89	-0.91	0.56	-0.92	-0.43
Other Current Assets	0.84	0.82	0.84	0.11	0.89	0.85	0.27	-0.87	0.94	0.54	0.94	-0.92	0.85	0.67	0.96		0.86	0.72	0.76	0.91	-0.92	0.88	-0.92	0.53	-0.91	-0.25
Other Stockholder Equity	0.96	0.96	0.96	0.33	0.97	0.61	0.63	-0.98	0.8	0.72	0.86	-0.73	0.92	0.93	0.85	0.86		0.95	0.9	0.87	-0.73	0.83	-0.73	0.81	-0.97	-0.57
Total Liab	0.96	0.97	0.96	0.51	0.93	0.45	0.77	-0.95	0.72	0.78	0.73	-0.61	0.91	1.0	0.74	0.72	0.95		0.93	0.79	-0.61	0.74	-0.61	0.92	-0.92	-0.62
Net Invested Capital	0.98	0.94	0.93	0.51	0.85	0.66	0.51	-0.93	0.68	0.94	0.81	-0.75	0.84	0.91	0.77	0.76	0.9	0.93		0.87	-0.75	0.86	-0.75	0.94	-0.86	-0.61
Total Current Assets	0.89	0.85	0.86	0.25	0.83	0.78	0.31	-0.9	0.79	0.76	0.95	-0.84	0.9	0.75	0.94	0.91	0.87	0.79	0.87		-0.84	0.99	-0.84	0.72	-0.87	-0.48
Capital Stock	-0.8	-0.76	-0.79	-0.03	-0.78	-0.96	-0.05	0.8	-0.89	-0.59	-0.92	1.0	-0.72	-0.54	-0.91	-0.92	-0.73	-0.61	-0.75	-0.84		-0.82	1.0	-0.48	0.8	0.28
Net Working Capital	0.86	0.79	0.79	0.27	0.76	0.8	0.22	-0.84	0.71	0.79	0.93	-0.82	0.83	0.7	0.89	0.88	0.83	0.74	0.86	0.99	-0.82		-0.82	0.7	-0.81	-0.45
Common Stock	-0.8	-0.76	-0.79	-0.03	-0.78	-0.96	-0.05	0.8	-0.89	-0.59	-0.92	1.0	-0.72	-0.54	-0.91	-0.92	-0.73	-0.61	-0.75	-0.84	1.0	-0.82		-0.48	0.8	0.28
Short Long Term Debt Total	0.88	0.86	0.83	0.69	0.73	0.37	0.67	-0.82	0.47	0.93	0.59	-0.48	0.75	0.94	0.56	0.53	0.81	0.92	0.94	0.72	-0.48	0.7	-0.48		-0.73	-0.65
Property Plant And Equipment Net	-0.95	-0.96	-0.98	-0.27	-1.0	-0.65	-0.62	0.98	-0.92	-0.62	-0.88	0.8	-0.96	-0.89	-0.92	-0.91	-0.97	-0.92	-0.86	-0.87	0.8	-0.81	0.8	-0.73		0.48
Current Deferred Revenue	-0.59	-0.64	-0.6	0.02	-0.47	-0.18	-0.43	0.6	-0.24	-0.6	-0.51	0.28	-0.55	-0.61	-0.43	-0.25	-0.57	-0.62	-0.61	-0.48	0.28	-0.45	0.28	-0.65	0.48

Click cells to compare fundamentals

Mirum Pharmaceuticals Account Relationship Matchups

Mirum Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	146.7M	240.9M	294.7M	352.9M	646.6M	679.0M
Other Current Liab	9.3M	14.0M	32.0M	54.2M	77.4M	81.3M
Total Current Liabilities	13.1M	18.5M	42.6M	64.7M	87.1M	91.4M
Total Stockholder Equity	(69.9M)	(173.2M)	120.2M	(392.8M)	248.7M	261.1M
Other Liab	36K	47.7M	129.9M	144.9M	166.6M	174.9M
Net Tangible Assets	130.3M	172.1M	101.5M	83.1M	95.5M	103.3M
Net Debt	(136.3M)	(138.8M)	(28.7M)	(25.8M)	21.8M	22.9M
Retained Earnings	(69.9M)	(173.2M)	(257.2M)	(392.8M)	(556.2M)	(528.4M)
Accounts Payable	3.4M	3.2M	9.2M	8.7M	7.4M	5.9M
Cash	140.0M	142.1M	31.3M	28.0M	286.3M	300.6M
Non Current Assets Total	27.3M	4.5M	128.1M	162.7M	259.1M	272.0M
Non Currrent Assets Other	324K	1.3M	101.8M	101.4M	4.2M	4.0M
Other Assets	324K	3.2M	101.8M	101.4M	1.0	0.95
Cash And Short Term Investments	140.0M	231.8M	156.5M	251.7M	286.3M	205.0M
Common Stock Shares Outstanding	23.0M	25.3M	30.3M	33.8M	40.9M	32.3M
Liabilities And Stockholders Equity	(53.5M)	(104.4M)	294.7M	(182.0M)	646.6M	679.0M
Non Current Liabilities Total	3.3M	50.3M	131.8M	146.1M	310.9M	326.4M
Capital Surpluse	200.1M	345.2M	377.4M	535.1M	615.3M	320.7M
Capital Lease Obligations	3.6M	3.3M	2.6M	2.2M	1.7M	2.5M
Other Current Assets	2.7M	9.1M	10.5M	8.9M	10.9M	7.7M
Other Stockholder Equity	(146.8M)	345.2M	377.4M	535.1M	803.3M	843.4M
Total Liab	16.4M	68.8M	174.4M	210.9M	398.0M	417.8M
Net Invested Capital	130.3M	172.1M	120.2M	142.0M	555.1M	582.8M
Property Plant And Equipment Gross	3.7M	3.2M	2.6M	2.3M	2.0M	2.5M
Total Current Assets	119.4M	236.4M	166.6M	190.2M	387.5M	211.2M
Accumulated Other Comprehensive Income	129K	83K	(35K)	(217K)	1.6M	1.7M
Non Current Liabilities Other	36K	50.3M	131.8M	146.1M	3.8M	3.7M
Net Working Capital	106.3M	217.9M	124.0M	125.5M	300.5M	169.3M
Short Term Debt	397K	1.3M	1.4M	1.9M	2.2M	1.3M
Property Plant Equipment	3.7M	1.3M	981K	914K	822.6K	1.1M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Mirum Pharmaceuticals is a strong investment it is important to analyze Mirum Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mirum Pharmaceuticals' future performance. For an informed investment choice regarding Mirum Stock, refer to the following important reports:

How To Invest In Mirum

Details

Is Mirum Stock a good investment?

Details

What is Mirum Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.

You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.08)

Revenue Per Share

6.513

Quarterly Revenue Growth

0.894

Return On Assets

(0.09)

Return On Equity

(0.40)

The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Mirum Historical Balance Sheet

Mirum Pharmaceuticals Inventory

23.43 Million

About Mirum Balance Sheet Analysis

Mirum Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Warrants

Mirum Pharmaceuticals balance sheet Correlations

Mirum Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Mirum Pharmaceuticals balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Accumulated Amortization	Total Assets
Other Current Liab	Total Current Liabilities
Total Stockholder Equity	Other Liab
Net Tangible Assets	Total Permanent Equity
Warrants	Noncontrolling Interest In Consolidated Entity
Net Debt	Retained Earnings
Accounts Payable	Cash
Non Current Assets Total	Non Currrent Assets Other
Other Assets	Long Term Debt
Cash And Short Term Investments	Good Will
Common Stock Total Equity	Retained Earnings Total Equity
Common Stock Shares Outstanding	Short Term Investments
Long Term Debt Total	Liabilities And Stockholders Equity
Non Current Liabilities Total	Capital Surpluse
Capital Lease Obligations	Negative Goodwill
Inventory	Other Current Assets
Other Stockholder Equity	Total Liab
Additional Paid In Capital	Deferred Long Term Liab
Net Invested Capital	Preferred Stock Redeemable
Long Term Investments	Property Plant And Equipment Gross
Short Long Term Debt	Preferred Stock Total Equity
Total Current Assets	Accumulated Other Comprehensive Income
Treasury Stock	Capital Stock
Non Current Liabilities Other	Accumulated Depreciation
Net Working Capital	Deferred Long Term Asset Charges
Short Term Debt	Intangible Assets
Common Stock	Temporary Equity Redeemable Noncontrolling Interests
Property Plant Equipment	Short Long Term Debt Total
Property Plant And Equipment Net	Current Deferred Revenue
Net Receivables

Total Current Liabilities	+ 1.0	Other Current Liab
Capital Stock	+ 1.0	Common Stock Total Equity
Common Stock	+ 1.0	Common Stock Total Equity
Total Liab	+ 1.0	Non Current Liabilities Total
Common Stock	+ 1.0	Capital Stock
Net Working Capital	+ 0.99	Total Current Assets

Property Plant And Equipment Net	- 1.0	Other Liab
Retained Earnings	- 1.0	Total Current Liabilities
Retained Earnings	- 0.99	Other Current Liab
Retained Earnings	- 0.99	Total Assets
Other Stockholder Equity	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Other Liab